CTI Announces Acquisition of Community Research

News   Feb 07, 2014

 
CTI Announces Acquisition of Community Research
 
 
 

RELATED ARTICLES

Tuberculosis Vaccine Trial Results Offer Potential for BCG Revaccination

News

The study is the first 'prevention of infection' trial conducted for tuberculosis, the world's leading infectious disease killer.

READ MORE

Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate Growth

News

Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.

READ MORE

Catalyst Biosciences Announces Positive Top-Line Data for Potential Hemophilia B Treatment

News

All individuals with severe hemophilia improved to mild hemophilia activity levels after only six daily doses with a continuous linear increase in Factor IX clotting activity. These results suggest that long-term dosing of SQ CB 2679d has the potential to maintain stable clotting activity in the high-mild hemophilia to normal range.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE